Torrent Pharmaceuticals presents a compelling bullish setup.

Driven by its consistent execution in the chronic therapy segment, particularly in cardiology, CNS, and gastroenterology. The company’s strong domestic brand equity, coupled with a high-margin specialty portfolio, enables устойчивый revenue visibility. Its India business continues to outperform industry growth, supported by deep doctor engagement and pricing power in key molecules. Additionally, Torrent’s calibrated expansion in emerging markets provides a diversified growth lever without overexposure to volatile geographies. From a financial standpoint, the company maintains a healthy balance sheet, robust operating margins, and disciplined capital allocation. Its focus on backward integration and cost optimization enhances EBITDA resilience even in pricing pressure environments. The US generics segment, though historically volatile, shows signs of stabilization with a selective product pipeline and compliance track record improving. The company’s strategic acquisitions in recent years have also started delivering synergies, strengthening its portfolio depth and market positioning. Technically, the stock often demonstrates strong support at key moving averages, with accumulation visible during market corrections—indicative of institutional interest. A sustained breakout above resistance zones could trigger momentum-driven upside. Given its blend of defensive earnings, strong cash flows, and improving global outlook, Torrent Pharma remains well-positioned for medium- to long-term value creation, making it an attractive candidate for accumulation on dips.